Overview
Ibogaine (12-methoxyibogamine) is an indole alkaloid — a tryptamine with two chiral centers — occurring predominantly in the root bark of Tabernanthe iboga, a shrub native to Central and West Africa, particularly Gabon and Cameroon. In research settings it is used as a hydrochloride salt, a white or slightly off-white powder; outside research settings, pulverized root bark or whole-alkaloid root-bark extract is sometimes used. The brochure distinguishes “ibogaine” (the chemical) from “iboga” (the plant).
After typical oral doses, ibogaine reaches peak plasma concentrations at about 2 hours, with a plasma half-life of about 7.5 hours. It is lipophilic and accumulates in fat, creating a peripheral reservoir that slowly redistributes into circulation. Its principal metabolite, noribogaine, is formed mainly by the liver enzyme CYP2D6, peaks around 6 hours, and has an estimated terminal half-life of 28–49 hours.
Psychological effects have been described in three phases: an acute dream-like state beginning 1–3 hours after ingestion and typically lasting 4–8 hours; a longer evaluative phase of roughly 8–20 hours, often in a low-stimulus environment; and a residual phase beginning about 12–24 hours after ingestion and lasting 24–72 hours or longer.
Origins and traditional context
Iboga is described in the brochure as a keystone species in the bioculture of the Congo Basin, used in traditional practices across the region for a very long period. In Gabon, the Republic of the Congo, the Democratic Republic of the Congo and the Rio Muni region of Equatorial Guinea, members of Bwiti and other religious traditions ingest T. iboga root for ceremonial and medicinal purposes. Ethnographic sources cited in the document record use among the Babongo, Apindji, Mitsogho, Massango, Puna and Fang peoples for medical, invigorative, spiritual and divinatory purposes — including heightening the senses during hunting, countering fatigue, mild anesthesia for stomach and tooth pain, and remedies for several common ailments. According to local narratives, the Babongo are credited with recognizing the psychoactive properties of iboga root and sharing that knowledge with neighboring Bantu peoples around the mid-19th century.
MAPS explicitly acknowledges the traditional cultures and knowledge keepers whose relationship with iboga long predates Western scientific interest and continues today, and notes that peer-reviewed literature does not capture that body of traditional knowledge, nor decades of protocol refinement by clinicians working in real-world settings.
History
Western documentation began in 1864, when French navy surgeon Griffon du Bellay brought T. iboga from Gabon to Paris. The species was taxonomically described in 1889 by Henri Ernest Baillon, and in 1901 two teams — Dybowski and Landrin, and Haller and Heckel — isolated ibogaine from the root bark. Early French researchers classified it as a stimulant.
Archival research cited in the brochure documents that ibogaine was commercialized in numerous early 20th-century retail medicines, among them Dragées Nyrdahl, Grains des Anémiques, Syséros, Viris Lucet, Ibobiose, Iperton and, from 1938, Lambarène. These were sold for neurasthenia, fatigue, convalescence, influenza, cardiac disorders, and as aphrodisiacs. On this account ibogaine is arguably the first commercialized psychedelic; Syséros remained available as late as 1997. A 1913 Mexican case report by Enrique O. Aragón describes treatment of a woman with severe alcoholism using an ibogaine-containing product, which complicates the common attribution of the discovery of anti-addictive effects solely to Howard Lotsof in 1962.[1]
Lambarène later became popular among athletes and was added to doping lists by the International Olympic Committee and other bodies. In the 1940s and 1950s researchers at Ciba Pharmaceuticals and CIA-affiliated investigators, including Harris Isbell in Lexington, Kentucky, studied ibogaine in animals and humans, in some cases within the contested MK-ULTRA program. Commercialization of Lambarène was forbidden in France in 1966; the brochure states the precise reasons remain unclear. Ibogaine then remained obscure until Howard Lotsof promoted it as an interruption of heroin withdrawal, which stimulated later scientific study.
Pharmacology
The brochure characterizes ibogaine as polypharmacological rather than acting through a single receptor. Ibogaine and noribogaine show low-micromolar affinities for the serotonin transporter, sodium channels, sigma-2 sites, NMDA receptors, 5-HT3 receptors, µ- and κ-opioid receptors, and α3β4 nicotinic acetylcholine receptors. Reported features include:
- Nicotinic α3β4 antagonism, proposed as a core substrate of reduced drug self-administration, with recent attention to the medial habenula–interpeduncular nucleus axis.
- Opioid receptors: multi-laboratory work characterizes ibogaine, noribogaine and 18-MC as functional µ-opioid antagonists; noribogaine has been described as a biased κ-opioid agonist.
- Serotonergic effects: noncompetitive inhibition of the serotonin transporter, unusual among SERT inhibitors, and pharmacochaperone activity for SERT and the dopamine transporter.
- Glutamatergic effects: noncompetitive NMDA antagonism.
- Cardiac ion channels: block of the hERG (KV11.1) potassium channel by ibogaine, noribogaine and voacangine at low-micromolar IC50 values, plus reduction of Nav1.5 sodium and L-type calcium currents at high concentrations.
- Neurotrophic effects: upregulation of glial cell line-derived neurotrophic factor (GDNF) is proposed as a mechanism for enduring effects, particularly in alcohol use disorder.
The document frames these actions as a hypothesized neurobiological “reset” of circuitry associated with substance use disorder, accompanied by a window of enhanced synaptic plasticity, while stating plainly that the neural mechanisms remain incompletely understood. Unlike methadone or buprenorphine, ibogaine is not a receptor-substitution therapy; three proposed therapeutic effects are attenuation of tolerance, reduction of withdrawal symptoms and suppression of craving.
Proposed therapeutic applications
Applications discussed in the brochure are investigational. They center on opioid use disorder and other substance use disorders, and extend to trauma-related conditions, including PTSD and traumatic brain injury. The document also notes an expanding literature touching treatment-resistant depression, neuropathic pain and other emerging neurological indications. It recommends that detoxification use be accompanied by counseling and referral to aftercare and community support.
Research evidence
Preclinical
A meta-analysis of 27 animal studies found reduced self-administration of opioids, cocaine and ethanol within 24 hours of ibogaine administration. Animal work also in